Erschienen in:
01.07.2014 | Special Report
Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update
verfasst von:
Yasuo Suzuki, Hajime Nawata, Satoshi Soen, Saeko Fujiwara, Hisanori Nakayama, Ikuko Tanaka, Keiichi Ozono, Akira Sagawa, Ryoichi Takayanagi, Hiroyuki Tanaka, Takami Miki, Naomi Masunari, Yoshiya Tanaka
Erschienen in:
Journal of Bone and Mineral Metabolism
|
Ausgabe 4/2014
Einloggen, um Zugang zu erhalten
Excerpt
Glucocorticoids (GCs) are widely used to treat various inflammatory, immunologic, and allergic disorders that cause rheumatic, respiratory, bowel, hepatic, neurological, renal, and skin diseases. Osteoporosis is the most common and important adverse effect of GC therapy, and fractures occur in 30–50 % of adult patients receiving long-term GC therapy [
1,
2]. Glucocorticoid-induced osteoporosis (GIO) is the most common type of secondary osteoporosis, and it occurs in patients of all ages, from children to the elderly. …